title: Does end-of-treatment FDG-PET provide any additional prognostic value to the pre-treatment NCCN-IPI score? Reply to Adams and Kwee.
authors.affiliation: Department of Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK.
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Bishton
authors.affiliation: Department of Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK.
authors.forename: Andrew K
authors.initials: AK
authors.lastname: McMillan
authors.affiliation: Department of Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK.
authors.forename: Christopher P
authors.initials: CP
authors.lastname: Fox
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols; D019788:Fluorodeoxyglucose F18; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse; D049268:Positron-Emission Tomography; D011379:Prognosis; D012189:Retrospective Studies
chemical_list: D019788:Fluorodeoxyglucose F18
keywords: National Comprehensive Cancer Network International Prognostic Index; diffuse large B cell lymphoma; positron emission tomography; prognostic factors